[September 15, 2015]

Breast Cancer Therapeutics Market Is Expected to Post a CAGR of 58.3% From 2015 to 2023: Transparency Market Research

Growth in the global breast cancer therapeutics market will be unprecedented, says a latest report by Transparency Market Research. The market is expected to post a CAGR of 58.3% between 2015 and 2023, as it grows from its 2015 valuation of 55.5 million to US$7,853.1 million by 2023. These findings are detailed in the report titled 'Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015-2023.'

Browse Report: http://www.transparencymarketresearch.com/breast-cancer-therapeutics-pipeline-analysis-market.html

The vigorous growth of the breast cancer therapeutics market comes as little wonder in the backdrop of the fact that the WHO has found breast cancer to be the second most prevalent type of cancer globally. The America Cancer Society expects about 231,840 women to be diagnosed with the disease in 2015 - and these figures are for the U.S. alone. Thus, the sheer rise in the prevalence of breast cancer makes it a space where novel molecules and therapies are imperative.

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5678

The report segments the global breast cancer therapeutics market on the basis of clinical study phases into: Phase I, phase II, and phase III drugs. Of these, the report closely evaluates breast cancer drugs that are currently in phase III of clinical trials. Phase III drugs that are studied in great detail in the breast cancer therapeutics market report are: Palbociclib (PD-0332991) + Exemestane, BKM120, Neratinib, DOXIL, NKTR-102, ABP (News - Alert) 980, NK105, CT-P6, and Olaparib.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/breast-cancer-therapeutics-pipeline-analysis-market.htm

Neratinib (Puma Biotechnology, Inc.), a clinical trial phase III drug, will rake in maximum revenue by 2023. The drug is important to the breast cancer therapeutics market because it is highly potent as an irreversible tyrosine kinase inhibitor (TKI). At the second place, in terms of revenue generation, will be Pfizer, Inc's Palbociclib, Fulvestrant.

Browse Article: http://www.transparencymarketresearch.com/article/breast-cancer-therapeutics-pipeline-analysis-market.htm

About TMR

Transparency Market Research (TMR) is a market intelligence company driven by high-pedigree consultants and researchers. TMR leverages its Syndicated Research, Custom Research, and Market Consulting expertise to help businesses make accurate decisions. TMR's exclusive blend of quantitative forecasting and trends analysis draws on proprietary data sources and techniques, while their data repository is continuously updated to reflect the latest trends.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150915006044/en/

[ Back To TMCnet.com's Homepage ]